The U.S. pharmaceutical industry has been in a deep recession for years, and analysts say the downturn is playing out with bigger and bigger companies taking market share.
In the fourth quarter, Pfizer, for instance, took its share of the global drug market by 17% from the fourth-quarter of 2016.
The biggest gainers are in the U.K., where the drugmaker increased its market share by 4.6% from its fourth-Q3 to its fourth.
The largest gainer was Gilead Sciences, up 13.5% from last year’s fourth quarter.
Pfizer and Gileads share jumped 21.6%.
In a survey of 500 analysts by research firm Kantar Worldpanel, analysts said the industry’s biggest gainer is AstraZeneca, up nearly 11% to 1.76 billion shares.
The stock gained nearly 6% over the past year.
AstraMedics was second, up more than 6% from a year ago.
The biggest gain for Pfizer was on its cancer drug Avastin, which jumped 13% to $1.092 billion.
Gileades was the third-largest gainer, up 12.6%, while Astra and AstraZymed were the fourth and fifth biggest gains, respectively.
The top 10 drugmakers rose a combined total of $2.5 billion, while Astrafarma rose $2 billion, according to Kantar.
The industry has seen a surge in its use of generics over the last several years, with prices for the generic versions of most drugs going down.
But in the last year, generics have also been increasingly priced at the higher end of the market, with generics on the market at a premium compared with brand-name drugs.
Last month, Pfizers CEO Ian Read said generics had “slightly” outperformed the brand-labeled versions of its drugs.
Pfizers’ generics prices, meanwhile, were much lower than what the brand label was for those same drugs.
Read also: Why some patients are still waiting to get access to a cancer drug